Healthcare Industry News: HSMN NewsFeed
News Release - March 31, 2017
Astellas Announces New President of Astellas US Technologies, Inc.NORTHBROOK, Ill., March 31, 2017 -- (Healthcare Sales & Marketing Network) -- Astellas today announced that John DeMay has been appointed president, Astellas US Technologies, Inc. (AUST). In this role, DeMay will be responsible for promoting collaboration and cooperation across Pharmaceutical Technology divisions functions in the Americas. He will also serve as the site manager for AUST based in Northbrook and will represent AUST in various Americas management activities. DeMay will also continue in his role as head of Project and Product Management Group reporting to Dr. Katsutoshi Nakamura, head of Project and Product Management within Pharmaceutical Technology. View photos
"John's background and broad experience in this area will help him meet the challenges of this new role, while continuing to grow the strong partnerships that exist within AUST and between AUST and its collaborators," said Nakamura. "He is dedicated to assuring stable global supply of clinical and commercial products for patients."
Previously, DeMay served as executive director, Pharmaceutical Technology Management for AUST. He joined Astellas in 2002 as an associate director of Technical Services and later served as director and senior director of the CMC Technology group within US Pharmaceutical Technology Management.
Throughout his 15-year career at Astellas, DeMay has played an important role in the chemistry, manufacturing and control (CMC) development and CMC project management. He has contributed to the development, introduction and stable supply of several new drug products and marketed products.
DeMay holds a Bachelor of Science in Biology degree with a Chemistry Minor from Michigan Technological University and a Bachelor of Science in Pharmacy degree from Ferris State University.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAstellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Announces Key Leadership Changes in Legal, Human Resources